Summary of safety in the initial 12-week randomised study
| Riociguat | Placebo | |
| Patients n | 12 | 6 |
| Any AE | 12 (100) | 4 (67) |
| Any study drug-related AE | 7 (58) | 3 (50) |
| AE-related deaths | 0 | 0 |
| Any SAE | 2 (17) | 0 |
| Any study drug-related SAE | 0 | 0 |
| Discontinuation of study drug due to AEs | 1 (8) | 0 |
| Discontinuation of study drug due to SAEs | 0 | 0 |
Data are presented as n (%) unless otherwise stated. AE: adverse event; SAE: serious adverse event.